An international multicenter efficacy and safety study of IqYmune in initial and maintenance treatment of patients with chronic inflammatory demyelinating polyradiculoneuropathy: PRISM study.

J Peripher Nerv Syst · 2020 · PMC7754365 · PMID 32808406

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

When reviewing results of the PRISM study in detail, Ig‐pre‐treated patients showed a numerical trend for a higher responder rate than Ig‐naïve patients (84.2% vs 69.6%) possibly reflecting the fact that Ig‐pre‐treated patients were selected for their positive clinical response to IVIg and consequently are more likely to respond again.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.